A federal appeals court has rejected a request from a drug testing industry association and a pharmaceutical company to block the Trump administration from moving forward with federal cannabis rescheduling while ongoing litigation challenging the reform is considered. “Petitioners have not satisfied the stringent requirements for a stay pending court review,” the U.S. Court of…...
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
